IBOV 205,430.33 ▲ 0.54% IPSA 10,970.29 ▼ 0.01% IPC MEX 68,929.72 ▲ 1.87% MERVAL 2,848,945 ▼ 0.35% COLCAP 2,566.28 ▼ 0.55% BVL PERÚ 60,210.69 ▼ 0.91% USD/BRL5.07▲ 0.13% USD/MXN18.47▼ 0.15% USD/CLP984.38▼ 0.05% USD/COP3,174▲ 0.10% USD/PEN3.43▼ 0.16% USD/ARS1,518▼ 0.02% USD/UYU40.13▲ 3.03% USD/PYG5,686▲ 3.29% USD/BOB11.61▲ 2.19% USD/DOP61.26▲ 3.05% USD/CRC448.47▲ 1.74% USD/GTQ7.65▲ 3.33% USD/HNL26.86▲ 3.30% USD/NIO36.62— 0.00% USD/VES877.92▼ 0.23% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 2.35% EUR/BRL5.69▼ 0.38% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 205,430.33 ▲ 0.54% IPSA 10,970.29 ▼ 0.01% IPC MEX 68,929.72 ▲ 1.87% MERVAL 2,848,945 ▼ 0.35% COLCAP 2,566.28 ▼ 0.55% BVL PERÚ 60,210.69 ▼ 0.91% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, October 18, 2026

Easter Island Discovery: The Anti-Aging Power of Rapamycin

By · May 16, 2024 · 2 min read

In the remote expanse of Chile’s Easter Island, scientists discovered a remarkable compound called Rapamycin.

This substance shows potential in extending human lifespan and combating age-related diseases.

Found in the island’s soil, Rapamycin is produced by a unique bacterium.

Researchers first noted its antifungal properties, but soon, broader health implications emerged.

A groundbreaking 2009 study revealed Rapamycin could extend mice lifespans by 9% to 14%, even when administered later in life.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “US avoids pledge to accept Brazil election result”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Another study found a 60% lifespan extension in mice treated with Rapamycin for just three months.

(Lance Hitchings on Rapamycin)

[arve url=”https://www.riotimesonline.com/wp-content/uploads/1715/55/RAPAMYCIN_-How-Easter-Island-Led-To-The-Discovery-of-the-mTOR-Pathway-2021.mp4″ title=”Rapamycin” /]

These results hint at significant anti-aging benefits, potentially adding years to human life if similar effects occur in humans.

Rapamycin inhibits the mTOR (mechanistic target of rapamycin) pathway, a critical cellular process controlling growth and metabolism.

By blocking mTOR, Rapamycin enables cells to remove damaged components and recycle materials.

This process is vital for maintaining cellular health and preventing diseases like cancer and Alzheimer’s.

Beyond longevity, Rapamycin offers other benefits.

It rejuvenates cells, stimulates hair growth, and reduces age-related conditions such as diabetes, cardiovascular diseases, and neurodegenerative disorders.

Clinical trials showed Rapamycin enhanced immune responses to vaccines and decreased infection rates.

However, Rapamycin poses challenges. High doses can suppress the immune system, leading to infection risks.

Researchers aim to find lower doses that offer anti-aging benefits without significant risks.

Ongoing trials focus on determining the optimal dosing and safety for long-term use.

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Easter Island Discovery: The Anti-Aging Power of Rapamycin

The discovery of Rapamycin highlights the potential of natural compounds in medical research.

While mainstream anti-aging applications are future goals, Rapamycin’s current uses in transplant medicine and cancer treatment showcase its therapeutic versatility.

Continued studies will clarify its role in medicine, potentially offering new ways to enhance longevity and quality of life.

Rapamycin’s journey from an Easter Island soil sample to a promising anti-aging therapy underscores the intersection of nature and science, offering hope for healthier, longer lives.

As research progresses, the potential benefits of Rapamycin could revolutionize medical approaches to aging and disease prevention.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

Read More from The Rio Times

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.